All In Biotech

Drug Trial Radar · NCT01898364

Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.

Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 19, 2013

Primary completion

Feb 25, 2015

Study completion Feb 25, 2015

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jul 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the safety and tolerability of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. Secondary Objective: To evaluate the pharmacokinetics, pharmacodynamics of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. To evaluate the effect of neoGAA on exploratory efficacy endpoints in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients.

Conditions

  • Pompe Disease
  • Glycogen Storage Disease Type II (GSD II)
  • Acid Maltase Deficiency

Interventions

  • GZ402666Drug

    Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: screening/baseline to Week 25
  2. Laboratory assessments including hematology, biochemistry and urinalysisTime frame: screening/baseline to Week 25
  3. Vital signsTime frame: screening/baseline to Week 25

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840006

    Phoenix, Arizona

  • Investigational Site Number 840010

    Jacksonville, Florida

  • Investigational Site Number 840001

    Kansas City, Kansas

  • Investigational Site Number 840008

    St Louis, Missouri

  • Investigational Site Number 840002

    Durham, North Carolina

  • Investigational Site Number 840009

    Dallas, Texas

  • Investigational Site Number 840003

    Fairfax, Virginia

  • Investigational Site Number 056001

    Leuven, Belgium

  • Investigational Site Number 208001

    København Ø, Denmark

  • Investigational Site Number 250001

    Marseille, France

  • Investigational Site Number 250003

    Nice, France

  • Investigational Site Number 250002

    Paris, France

  • Investigational Site Number 276003

    Mainz, Germany

  • Investigational Site Number 276001

    München, Germany

  • Investigational Site Number 276002

    Münster, Germany

  • Investigational Site Number 528001

    Rotterdam, Netherlands

  • Investigational Site Number 826003

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.